Efficacy News and Research

RSS

Severe symptoms result in high titers of SARS-CoV-2 antibodies

Scientists have focused on determining the cause-effect relationship between SARS-CoV-2 antibody titers and COVID-19 disease severity.

9 May 2022

Targeting interleukin-6 could help reduce immune-related adverse events from immunotherapy

Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6).

9 May 2022

COVID-19 booster or additional primary vaccination dose against SARS-CoV-2 Omicron in nursing home occupants

A recent study assessed the efficacy of SARS-CoV-2 primary series vaccination, additional initial dose, or booster shot against the SARS-CoV-2 Omicron infection in the nursing home.

9 May 2022

How new Insights into ESR1 Mutant Breast Cancers may lead to Novel Therapy Targets

In this interview, we speak to Steffi Oesterreich, PH.D., from the University of Pittsburgh, about how new insights into a gene mutation present in 20-30% of breast cancer recurrences may have a silver lining, leading to novel treatment opportunities.

9 May 2022

Effectiveness of BNT162b2 third dose against Omicron-associated severe disease

Researchers analyzed the effectiveness of the SARS-CoV-2 BNT162b2 third vaccine dose against SARS-CoV-2 Omicron-induced severe infection nearly seven months post-vaccination.

9 May 2022

Benefit from convalescent plasma shown in COVID outpatient trial

Researchers have conducted a double-blind, multicentre, randomized, controlled trial, which is known as Convalescent Plasma to Limit SARS-CoV-2 Associated Complications Study to evaluate if early COVID-19 plasma treatment could reduce disease progression and, thereby, reduce hospitalization rate.

9 May 2022

ZF2001 vaccine safe and effective against symptomatic and severe-to-critical COVID

A new study published in the New England Journal of Medicine has discussed the efficacy and safety profile of the ZF2001 vaccine in adults, based on a randomized, placebo-controlled, multinational, double-blind phase 3 trial.

9 May 2022

Study confirms accuracy of new generation GastroPanel® test

A clinical validation study conducted at Oulu University Hospital (OUH) has confirmed the high accuracy of BIOHIT Oyj’s new generation GastroPanel® test for the diagnosis of atrophic gastritis (AG) and Helicobacter pylori (Hp) infection in patients referred for gastroscopy.

From BIOHIT HealthCare Ltd 6 May 2022

Marine bioactive compounds against SARS-CoV-2

A new review paper published in the journal Environmental Science and Pollution Research aimed to determine the possibilities of using biologically active compounds derived from various chemical classes of marine organisms against SARS-CoV-2 infection at various stages of the life cycle of the virus.

6 May 2022

Evaluating the findings of phase 3 clinical trial of plant-based COVID-19 vaccine

A new study has presented the safety and efficacy profiles of a plant-based adjuvanted coronavirus disease 2019 (COVID-19) vaccine in human participants.

5 May 2022

Effects of diet on COVID-19 outcomes

A new study explores the effects of diet on COVID-19 outcomes.

5 May 2022

Results indicate that Omicron infection induces low levels of neutralizing antibodies in immunocompetent individuals

Researchers assessed the induction of variant-specific neutralizing antibodies against the SARS-CoV-2 spike and nucleocapsid proteins of several SARS-CoV-2 strains.

5 May 2022

Study assesses the efficacy and safety of lithium treatment in patients infected with severe SARS-CoV-2

Researchers assessed the efficacy and safety of using lithium for coronavirus disease 2019 (COVID-19) treatment.

5 May 2022

Evaluation of the potential of new and repurposed TB vaccines

A new study evaluated effective vaccination strategies for two TB vaccines, M72/AS01E and BCG.

5 May 2022

Efficacy and safety of a 3rd dose of mRNA-1273 SARS-CoV-2 vaccine

In a recent study posted to the Research Square* preprint server, researchers tested the safety and immunogenicity of a third dose of coronavirus disease 2019 (COVID-19) prototype messenger ribonucleic acid (mRNA)-1273 versus a variant vaccine and a bivalent vaccine formulation.

5 May 2022

Efficacy News and Research

Severe symptoms result in high titers of SARS-CoV-2 antibodies

Targeting interleukin-6 could help reduce immune-related adverse events from immunotherapy

COVID-19 booster or additional primary vaccination dose against SARS-CoV-2 Omicron in nursing home occupants

How new Insights into ESR1 Mutant Breast Cancers may lead to Novel Therapy Targets

Effectiveness of BNT162b2 third dose against Omicron-associated severe disease

Benefit from convalescent plasma shown in COVID outpatient trial

ZF2001 vaccine safe and effective against symptomatic and severe-to-critical COVID

Study confirms accuracy of new generation GastroPanel® test

Marine bioactive compounds against SARS-CoV-2

Evaluating the findings of phase 3 clinical trial of plant-based COVID-19 vaccine

Effects of diet on COVID-19 outcomes

Results indicate that Omicron infection induces low levels of neutralizing antibodies in immunocompetent individuals

Study assesses the efficacy and safety of lithium treatment in patients infected with severe SARS-CoV-2

Evaluation of the potential of new and repurposed TB vaccines

Efficacy and safety of a 3rd dose of mRNA-1273 SARS-CoV-2 vaccine

Proper fit crucial for optimal face mask protection

New model can predict drug-drug interactions based on drug-induced gene expression signatures

Study identifies a protein in Mycobacterium tuberculosis that contributes to drug tolerance

UCSF surgeons demonstrate the feasibility and efficacy of novel scarless Adam's apple surgery

Bacteria-mediated oral delivery of viral replicon-based mRNA vaccines

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News